Barclays’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-13,278
| Closed | -$1.08K | – | 5674 |
|
|
2025
Q1 | $1.08K | Hold |
13,278
| – | – | ﹤0.01% | 5045 |
|
|
2024
Q4 | $9.9K | Hold |
13,278
| – | – | ﹤0.01% | 4997 |
|
|
2024
Q3 | $16.2K | Sell |
13,278
-179
| -1% | -$285 | ﹤0.01% | 4921 |
|
|
2024
Q2 | $27.9K | Sell |
13,457
-17,016
| -56% | -$40.1K | ﹤0.01% | 4381 |
|
|
2024
Q1 | $111K | Sell |
30,473
-16,500
| -35% | -$63.3K | ﹤0.01% | 4395 |
|
|
2023
Q4 | $141K | Buy |
46,973
+29,013
| +162% | +$58.8K | ﹤0.01% | 4543 |
|
|
2023
Q3 | $38.6K | Sell |
17,960
-203
| -1% | -$811 | ﹤0.01% | 3970 |
|
|
2023
Q2 | $102K | Sell |
18,163
-3,485
| -16% | -$27.3K | ﹤0.01% | 3554 |
|
|
2023
Q1 | $131K | Buy |
21,648
+328
| +2% | +$2.28K | ﹤0.01% | 4038 |
|
|
2022
Q4 | $122K | Buy |
21,320
+7,324
| +52% | +$41.1K | ﹤0.01% | 4117 |
|
|
2022
Q3 | $76K | Buy |
13,996
+718
| +5% | +$3.64K | ﹤0.01% | 3640 |
|
|
2022
Q2 | $50K | Sell |
13,278
-3,717
| -22% | -$13.8K | ﹤0.01% | 4034 |
|
|
2022
Q1 | $106K | Buy |
+16,995
| New | +$173K | ﹤0.01% | 3754 |
|
Barclays's OMGA Position: Q2 2025 in Review
Barclays sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q2 2025, closing a stake of 13,278 shares — an estimated $1.08K sold.
Barclays first reported a position in OMGA in Q1 2022 and held it in 13 quarters. The position peaked at $141K in Q4 2023. 1 fund tracked by Wall St. Rank holds OMGA as of Q2 2025.
- Barclays reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Barclays sold 13,278 Omega Therapeutics, Inc. Common Stock shares in Q2 2025, an estimated $1.08K.
- Barclays first reported a position in Omega Therapeutics, Inc. Common Stock in Q1 2022 and held it in 13 quarters.
- Barclays's Omega Therapeutics, Inc. Common Stock position peaked at $141K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q2 2025.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.